[1]Molecules,2018,vol.23,#5,
[1]Patent:WO2017/136348,2017,A1,
[1]Patent:WO2017/136348,2017,A1,
[1]Patent:WO2015/65891,2015,A1
[1]Patent:WO2015/65891,2015,A1
[1]Patent:WO2015/65891,2015,A1
[1]Patent:WO2015/65891,2015,A1
[1]Patent:WO2015/65891,2015,A1.Locationinpatent:Paragraph00174;00175;00176
Title: A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism.
Journal: Neuroscience and biobehavioral reviews 20111001
Title: Positive emotional learning is regulated in the medial prefrontal cortex by GluN2B-containing NMDA receptors.
Journal: Neuroscience 20110929
Title: The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats.
Journal: Neurobiology of aging 20110401
Title: Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13.
Journal: Neuroreport 20090826
Title: A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus.
Journal: Neuropharmacology 20081201
Title: Antinociceptive action of GLYX-13: an N-methyl-D-aspartate receptor glycine site partial agonist.
Journal: Neuroreport 20080702
Title: GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator.
Journal: Neuropharmacology 20051201
Title: Burgdorf J, et al. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. Neuroscience. 2015 Nov 12;308:202-11.
